GeneOne Life Science, Inc. (KRX:011000)

GeneOne Life Science Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1,198	1,180	9,111	13,261	22,310	62,432
Short-Term Investments	2,576	566.19	406.6	32,342	85,094	28,086
Trading Asset Securities	170.58	-	470.79	-	-	-
Cash & Short-Term Investments	3,944	1,746	9,988	45,603	107,404	90,518
Cash Growth	-54.51%	-82.52%	-78.10%	-57.54%	18.65%	417.94%
Accounts Receivable	4,932	7,182	6,624	8,980	7,438	7,408
Other Receivables	142.09	1,050	948.44	1,598	1,975	374.05
Receivables	5,150	8,310	7,652	10,659	10,091	8,401
Inventory	16,654	16,511	14,897	14,864	10,688	8,299
Prepaid Expenses	1,330	1,542	1,225	1,145	706.46	1,226
Other Current Assets	485.87	525.52	811	793.08	5,744	315.08
Total Current Assets	27,564	28,635	34,573	73,063	134,633	108,760
Property, Plant & Equipment	112,765	117,730	111,399	144,369	110,382	22,427
Long-Term Investments	16.66	18.5	50.39	147.49	437.33	710.58
Other Intangible Assets	195.88	189.96	385.99	563.91	643.1	683.11
Long-Term Deferred Tax Assets	21.65	21.71	13.28	36.42	14.24	154.29
Other Long-Term Assets	3,668	4,739	4,586	4,687	4,735	3,750
Total Assets	144,232	151,334	151,008	222,867	250,857	136,571
Accounts Payable	22,070	20,176	10,066	7,493	17,531	6,881
Accrued Expenses	4,992	4,910	1,971	2,327	1,173	931.56
Short-Term Debt	5,313	3,377	2,405	12,246	9,754	15,634
Current Portion of Leases	2,912	2,895	2,396	1,911	1,543	1,337
Other Current Liabilities	8,535	11,147	6,029	9,858	4,758	11,920
Total Current Liabilities	43,823	42,506	22,867	33,836	34,759	36,705
Long-Term Debt	18,064	16,373	6,273	-	-	-
Long-Term Leases	3,882	4,480	6,085	5,509	7,103	794.09
Long-Term Deferred Tax Liabilities	154.47	154.83	323.98	457.33	144.32	-
Other Long-Term Liabilities	1,894	2,192	1,872	1,594	1,524	473.64
Total Liabilities	67,855	65,729	39,518	41,395	44,350	38,062
Common Stock	80,039	80,039	78,474	77,752	77,479	44,771
Additional Paid-In Capital	217,579	217,579	215,555	214,299	209,871	117,319
Retained Earnings	-273,686	-264,848	-216,231	-137,155	-98,241	-81,567
Treasury Stock	-2,955	-2,955	-2,955	-2,955	-2,955	-2,371
Comprehensive Income & Other	55,399	55,791	36,647	29,531	20,353	20,357
Shareholders' Equity	76,377	85,605	111,489	181,471	206,507	98,509
Total Liabilities & Equity	144,232	151,334	151,008	222,867	250,857	136,571
Total Debt	30,171	27,126	17,160	19,666	18,400	17,766
Net Cash (Debt)	-26,227	-25,379	-7,171	25,937	89,004	72,752
Net Cash Growth	-	-	-	-70.86%	22.34%	2333.27%
Net Cash Per Share	-328.51	-319.41	-92.24	334.73	1198.84	1205.09
Filing Date Shares Outstanding	79.83	79.83	78.26	77.54	77.27	66.9
Total Common Shares Outstanding	79.83	79.83	78.26	77.54	77.27	66.9
Working Capital	-16,259	-13,870	11,705	39,227	99,875	72,055
Book Value Per Share	956.75	1072.35	1424.52	2340.29	2672.55	1472.58
Tangible Book Value	76,181	85,415	111,103	180,907	205,864	97,826
Tangible Book Value Per Share	954.29	1069.97	1419.59	2333.02	2664.23	1462.37
Land	3,709	3,720	3,139	4,081	3,817	3,503
Buildings	76,487	76,192	63,374	1,403	1,331	1,328
Machinery	57,975	55,318	48,599	15,199	11,775	9,776
Construction In Progress	-	-	-	104,661	78,283	11,489
Leasehold Improvements	17,395	16,414	14,867	13,139	12,124	6,739

Source: S&P Global Market Intelligence. Standard template. Financial Sources.